Acurx Pharmaceuticals Inc. (ACXP): Net earnings per share (EPS TTM)

The development of antibiotics for intensive care units provides Acurx Pharmaceuticals (ACXP) with stable hospital demand, establishing a strong brand reputation among physicians. The TTM net income per share confirms this trend, with the current value standing at -2.32. The picture is completed by prolonged clinical trials and the fight against resistance, which require constant investment in R&D to protect patents.

ACXP Acurx Pharmaceuticals Earnings per share for the trailing year (07/04/2022 - 11/15/2026)

Acurx - analytical breakdowns and key metrics (ACXP)

- stock price and consensus target price:

Stock Price Acurx Pharmaceuticals Inc.|ACXP - Analyst Median Target

- stock exchange capitalization data:

Market Capitalization Acurx Pharmaceuticals, Inc.|ACXP - Real Price to Acquire Entire Company

- business book valuation details:

Net Assets per Single Share Acurx Pharmaceuticals|ACXP - Accounting Value of Company|Market Value to Book Value Ratio acurxpharma.com|ACXP - Company Assets

- debt and liquidity data:

- earnings and multiples data:

ACXP - Net Income|Future Profit Acurx Pharmaceuticals|ACXP - P/E Multiple|Future Price to Earnings Acurx Pharmaceuticals, Inc.|ACXP - Growth-Adjusted Payback Ratio|Enterprise Value to EBITDA Ratio Acurx Pharmaceuticals|ACXP - Operating profit before amortization|Net earnings per share for the last 12 months Acurx Pharmaceuticals|ACXP - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months acurxpharma.com|ACXP - Earnings per share trend in current year|Earnings growth forecast for next year Acurx Pharmaceuticals

- issuer revenue and sales details:

ACXP - Company Sales Revenue|Projected Sales Volume Acurx Pharmaceuticals|ACXP - P/S Multiple|Price-to-Projected Revenue Ratio Acurx Pharmaceuticals, Inc.

Basic company analysis:ACXP - Acurx Pharmaceuticals

Manufactured products of Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals focuses on developing innovative antibiotics to combat resistant pathogens. This indicator calculates the aggregate net income over a rolling year divided by the total number of shares. This metric allows for an assessment of the real return on each share of capital, eliminating distortions from one-time payments. Investors use this calculation to determine the fair value of the asset and analyze the risks of overpayment. The trend in fundamental earnings per share TTM reflects the financial efficiency of developing targeted drugs.

Competitors of Acurx Pharmaceuticals

Armata Pharmaceuticals Inc - Net earnings per share (EPS TTM)